Close menu




January 31st, 2023 | 14:33 CET

This new project changes everything: Deutsche Bank, Aspermont, Alibaba

  • Digitization
  • Innovations
  • Technology
  • Investments
Photo credits: pixabay.com

When processes go digital, great opportunities arise: automation and scaling can ensure growth and turn established business models into high-flyers. But which companies should investors actively support in their transformation? Where is there real potential for investors, and where are companies just spreading buzzwords? We highlight three stocks for you.

time to read: 3 minutes | Author: Nico Popp
ISIN: DEUTSCHE BANK AG NA O.N. | DE0005140008 , ALIBABA GR.HLDG SP.ADR 8 | US01609W1027 , ASPERMONT LTD | AU000000ASP3

Table of contents:


    Jared Scharf, CEO, Desert Gold Ventures Inc.
    "[...] We have built one of the largest land packages of any non-producer in the belt at over 440 sq.km and have made more than 25 gold discoveries on the property to date with 5 of these discoveries totaling about 1.1 million ounces of gold resources. [...]" Jared Scharf, CEO, Desert Gold Ventures Inc.

    Full interview

     

    Deutsche Bank: How digital is the share?

    Deutsche Bank's share will be among the winners of 2023. Last month alone, the stock went up by around 11%. Over a six-month period, it has even risen by more than 45%. The reason for the share price rally is the interest rate turnaround. The higher the interest rates, the better banks can earn money with their bread-and-butter loans business. Investment banking also remained robust until the end - there was little sign of a crisis. But Deutsche Bank still has room for improvement in terms of returns. The solution to this problem is said to lie in ongoing digitization.

    Years ago, the Company announced it wanted to focus more on areas where it could offer customers the greatest added value. Digitization is to play a significant role in this. In this way, security is to increase, and costs are to decrease. In order to bring a breath of fresh air into the bank, Deutsche Bank already sought increased cooperation with startups a few years ago. Anyone logging into their account today will quickly find such offers - be it around interest solutions or in other areas. So Deutsche Bank is on the right track. However, the digitization strategy will not bring the big breakthrough for shareholders. The reason: Deutsche Bank is too big and sluggish for individual projects to make such a big impact. However, the share remains solid.

    Aspermont: Digital financing platform exceeds expectations

    The Australian mediatech company Aspermont is more than solidly positioned. The Company comes from the traditional publishing business and stands, among others, for the renowned brands Mining Journal and Mining Magazine. In addition, Aspermont offers numerous other solutions for farmers, industrial companies and customers from the raw materials sector. A few years ago, Aspermont launched its digitization strategy and now rolls out its content predominantly digitally. The business relationships accumulated over decades are now also paying off in the event business, which Aspermont is driving both in physical presence and digitally. In 2022, Aspermont launched Blu Horseshoe, a financing platform with renowned partners, which has already processed 118 transactions in the first four months of its existence.

    The Company sees this development as trend-setting. The digital platform is likely to be implementable in other markets as well. Proof that there is a market for such solutions has been provided. Coupled with the attractive media business, trade shows and other events, Aspermont offers comprehensive solutions for companies in the commodities sector and for growth companies in general. The research portal researchanalyst.com currently sees the stock as attractive: "The price-to-sales ratio of 3 with organic sales growth of 20% and margins of over 50% compares favorably with the peer group," according to the latest report.

    Innovation is a top priority at Deutsche Bank. Photo: Deutsche Bank

    Alibaba: End of the line?

    The success of Alibaba, among others, shows that it can pay off to advance several synergistic and, at the same time, digital business areas. In addition to eCommerce and auctions, the Company also indirectly offers payment services, cloud solutions and all kinds of other projects. Customers can, therefore, hardly avoid Alibaba. Especially in China, the Company is strong and generates almost 70% of its sales. Due to the pandemic, economic activity in China weakened in 2022. Alibaba also felt the impact - for the first time in years, the Company did not publish full sales results for Singles Day. The eCommerce giant and Amazon clone also failed to provide a detailed outlook for 2023. The stock gained after the turn of the year but is currently consolidating. Even a share buyback program cannot stabilize the share price at present. In the long term, there is potential here, but in the short term, it can become turbulent.


    Things look much more relaxed at mediatech hopeful Aspermont - the share price has been fixed around EUR 0.013 for months. This boredom can be a solid starting point for all investors convinced of the scaling story at Aspermont. For stocks such as Deutsche Bank and Alibaba, the drop seems more significant, given recent gains. Aspermont is also worth closer analysis for investors who otherwise tend to back blue chips.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by André Will-Laudien on April 24th, 2024 | 07:00 CEST

    Takeover rumors for biotech shares: BioNTech, Formycon, Cardiol Therapeutics and Novo Nordisk in focus

    • Biotechnology
    • Pharma
    • Innovations
    • Cancer

    The biotech sector has significantly lagged behind the performance of artificial intelligence and high-tech this year. This is due to high inflation, which in turn has made an imminent interest rate cut unlikely. Nevertheless, Germany's economic conditions are deteriorating dramatically, particularly due to the ongoing geopolitical conflicts. It should, therefore, come as no surprise if the ECB announces an "emergency interest rate cut" in the summer. That would then be the starting signal for a major reshuffle out of the best performers of recent months and into the long-neglected biotech segment. We have selected a few interesting stocks.

    Read

    Commented by André Will-Laudien on April 23rd, 2024 | 07:45 CEST

    Attention: DAX dividends! Car stocks pay out: Mercedes-Benz, MS Industrie, VW and BMW

    • Technology
    • hightech
    • Automotive
    • Electromobility

    The DAX 40 index has gone into reverse gear in recent weeks. In addition to the high-tech and artificial intelligence sectors, the multi-month bull market also included defense stocks in the interim phase. There is no real reason to celebrate among automotive stocks, as an expected decline in GDP also means reduced household budgets. This translates to fewer new vehicle sales, with many electric vehicles produced in bulk occupying important showroom space from dealers for months. The pain is increasing, and those looking to sell vehicles find themselves in ruinous discount battles with cheap Chinese imports. However, there appears to be a glimmer of hope on the horizon: interest rate cuts! They are expected in the second half of the year. We analyze the current situation.

    Read

    Commented by Fabian Lorenz on April 23rd, 2024 | 07:00 CEST

    TAKEOVER FEVER for biotech shares! Evotec, Bayer, Vidac Pharma - Who will follow Morphosys?

    • Biotechnology
    • Pharma
    • Innovations
    • Cancer

    There is takeover fever in the biotech sector. Genmab recently announced the acquisition of ProfoundBio, the US biotech company developing ovarian and endometrial cancer drugs, for USD 1.8 billion. With Morphosys, the takeover carousel is also turning in Germany. Who is the next candidate? Evotec is often mentioned. Due to unauthorized insider trading, the biotech company's shares have come under fire this year and offer an interesting entry opportunity. Vidac Pharma also impresses operationally. The Company's new approach has the potential to revolutionize cancer treatment. The study results of the past few months are very promising. Bayer shares surprised investors yesterday as one of the day's winners in the DAX. Is the Leverkusen-based company's stock about to take off?

    Read